Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration - PubMed Eyes treated with pegcetacoplan after 1 year had a 37% reduction in GA growth rate compared with their prior annual growth rate. Pegcetacoplan slowed the growth for foveal and non-foveal GA at a…

New real-world data show avacincaptad pegol (Izervay) is safe in GA, with no inflammation or endophthalmitis and only ~6% annual CNV risk—reassuring results beyond clinical trials.

#GeographicAtrophy #AvacincaptadPegol #Ophthalmology #RealWorldEvidence #Innovation buff.ly/mSnVtjg